EU approves Eylea (aflibercept solution for injection into the eye) to treat myopic choroidal neovascularisation- Bayer HealthCare
Bayer has received approval from the European Commission for Eylea (aflibercept solution for injection into the eye) in a fifth indication. Eylea is now approved for the treatment of visual impairment due to myopic choroidal neovascularisation (myopic CNV). Myopic CNV is a disease of the retina associated with high degrees of myopia (near-sightedness) and frequently affects people of working age. Bayer plans for an immediate introduction to the market with Germany being one of the first launch countries in Europe.
Aflibercept is already approved for the treatment of patients with wet age-related macular degeneration, for the treatment of visual impairment due to diabetic macular oedema, and for the treatment of visual impairment due to macular oedema secondary to retinal vein occlusion (branch RVO or central RVO). Aflibercept had already been approved in Japan for the treatment of visual impairment due to myopic CNV.
Learning Zones
The Learning Zones are an educational resource for healthcare professionals that provide medical information on the epidemiology, pathophysiology and burden of disease, as well as diagnostic techniques and treatment regimens.
3 mins